SYNALAR (fluocinolone acetonide) by Eurofarma Laboratórios is corticosteroid hormone receptor agonists [moa]. First approved in 1963.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
SYNALAR is a topical corticosteroid cream containing fluocinolone acetonide, a synthetic corticosteroid that acts as a hormone receptor agonist. It is indicated for inflammatory and pruritic dermatological conditions where topical corticosteroid therapy is appropriate. The drug works by binding to glucocorticoid receptors to reduce inflammation, itching, and associated skin symptoms.
As a legacy topical corticosteroid approaching loss of exclusivity, career growth is constrained; brand teams are typically smaller and focused on defending market share.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant
Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study
Worked on SYNALAR at Eurofarma Laboratórios? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
SYNALAR offers limited career growth as a legacy topical corticosteroid in LOE phase; roles are typically focused on defensive marketing and transition planning rather than innovation. Career progression on this product is constrained; professionals should seek cross-portfolio development or transition opportunities within the sponsor organization.